Why the study?
Does glucose absorption from peritoneal dialysis solutions increase cardiometabolic risk in patients with stage 5 chronic kidney disease?
Does glucose absorption from peritoneal dialysis solutions increase cardiometabolic risk in patients with stage 5 chronic kidney disease?
This review highlights the potential cardiometabolic risks associated with glucose absorption from peritoneal dialysis solutions and discusses strategies to mitigate these effects.
Answers are grounded in this paper and cite their sources.
May warrant caution with glucose-based peritoneal dialysis in diabetics; leaves open the cardiometabolic risk hypothesis pending prospective trials.
Peritoneal dialysis (PD) is a well-established form of therapy for stage 5 chronic kidney disease requiring renal replacement therapy. D-Glucose has been used successfully for several decades as the osmotic agent employed in dialysis solutions to achieve adequate fluid removal. The absorption of 100-200 grams of glucose per day has been suggested as potentially increasing cardiometabolic risk, particularly in patients with diabetes. Supporting and undermining evidence for this hypothesis is reviewed, with a focus on the role of glucose absorption in changes in body composition, dyslipidemia, and glycemic control in diabetic PD patients. Clinical strategies to optimize fluid removal while minimizing the metabolic impact of glucose absorption are also discussed.
No takes yet. Share an insight, caveat, or question.
Clifford J. Holmes (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: